EUROPEAN JOURNAL OF BREAST HEALTH, vol.18, no.1, pp.63-73, 2022 (ESCI)
Objective: This study was designed to investigate treatment satisfaction in patients and Health Care Professionals (HCP) and to evaluate the safety and tolerability of subcutaneous (SC) trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC).